'David Rind, chief medical officer of the Institute for Clinical and Economic Review, an influential non-profit that assesses drug prices, wrote last month that it came with “an enormous price tag” despite failing its primary endpoint as measured by a motor function test.'

https://www.ft.com/content/d5a1f476-56e9-42c9-b029-cde1e11fa89e